Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't want to ruin anybody's day, but projected to go down to $150. https://news.yahoo.com/moderna-stock-fell-to-overly-high-expectations-jefferies-managing-director-200709404.html
This structured four-month downtrend looks relentless and irreversible, similar to the downtrend over the same timeframe with SRNE, which I guarantee you is relentless and beyond hope. Some bigger company needs to buy them and give them direction. We are a big company, even if not a huge company, we've been around for a short time but have accomplished much, but investors seem to have become disenchanted with this covid shtick. They think the pandemic is petering out whether it is or not. It seems to me to be. It will be 2-5 years before MRNA has other products on the market, so other revenue. I don't think this is the work of the HF's and MM's, I think "retail" investors are losing interest.
A share buyback would be nice. It would raise the share price. Maybe. Announcing a dividend would be really nice. With a yield of 1.5 to 2.5%, say, similar to Pfizer, so a payout of 10% to 20% on EPS, but yeah, Pfizer has an even bigger bank account. After all, they've been around for about 150 years. It may be a little early for that. Things like this would help us little guys.
It looks like it's bottoming.
when?
MRNA, BNTX, and even PFE are down while NVAX is up. What's up?
I have owned MRNA shares for a few months now. Now also PFE. BNTX is good, I mention that in passing, they collaborate with PFE. NVAX may have some big potential, but for the time being, they are struggling share price wise. Sorrento Therapeutics, which I escaped from a few months ago (!), is, well, in the toilet. So here we are. MRNA and BNTX seem to move in unison more or less, I mention that in passing, as it is well, really neither here nor there. So here we are. MRNA has been moving sluggishly ever since it suffered a few bad impacts in Nov, Dec: the damned Merck pill, then the, superior to it, Pfizer pill! Welllll, as far as Pfizer is concerned that is pretty much priced in, and as far as MRNA is concerned pretty much likewise in the opposite direction. And one or two other things, so where do things go from here? A new year and a new quarter are starting. There may be new purchases of shares by the big funds, I don't know. The next quarterly report is coming up and we need to not blow it bandying about oversized expectations. Yeah, one thing weighing MRNA down has been those lawsuits (bad), but on the political front, a lot of noise, not sure I see any signals there. Damn, MRNA should be doing better than it is. It's a good company with a good product, safe, by the way, maybe not 100% safe, but safe, and the production line is working, soooooo?
I haven't posted to this forum in a few months. I still own some SRNE shares. The entire biopharma world is now topsy turvy. Methinks the best thing to have happen for Sorrento is a buyout, I mean it. The CEO is a douchebag. The BOD is clueless. This company needs direction from a new owner, like Pfizer if they would want us or some other pharmaceutical company. Really needed here is proportion and perspective.
Thanks for the well wishes. Looking forward to Thanksgiving. The for- / fore- thing is more easily understood by comparison with German, where you have the _separable_ prefix vor (meaning "in front of") versus the _inseparable_ prefix ver meaning a few things... Comparison words are: verbieten (past participle verboten) = forbid and vergessen = forget. Fore- type words in English include: foreword, forego (go in front of, precede), foretell, forecast, foretaste, foreskin, forehead. As for the for- type words, notice one that is in parallel with German: forlorn, compare German verlieren, verlor, verloren = lose, lost, lost. Of course, forget, forgive (German: vergessen, vergeben), etc. As for investing, I balanced or diversified my biopharma holdings, but nothing works in biopharma unless you have your ear to the ground noticing what the big boys are doing and why, so you can get ahead of the game. Tough. the smarty pants-es knew what was coming down the pike from Merck a week before and the rest is history. Hopefully, this will all iron itself out in a few months. And, of course, forgo, forwent, forgone. A foregone conclusion, but I will forgo this opportunity. I really! forwent this opportunity.
It's a word that is not used very much, but when it is used, it means what it says. BTW, per forlorn and "lose", "lost", one notices rhotacism operating here. In the Germanic languages you have mild, random rhotacism operating in the West Germanic languages (English, German), strongly in the North ones (compare English iron, German Eisen, Swedish jern), and not at all in the now archaic or vestigial East ones (they died out). Per Italic ones, to the south, Oscan no rhotacism, in the central part, Latin fairly strong rhotacism where not blocked, and in Umbrian very strong. See, look, English: was, were, but in German only war, waren, waere. But I think the past participle (been) = gewesen may be the flip side there.
https://www.wionews.com/world/exclusive-south-african-company-hired-to-decode-moderna-vaccines-recipe-talks-to-wion-424559 What to make of this? First of all, it will take them three years. Etc.
So what? When will the stock recover? Actually, likewise for BNTX and, in passing, VXRT and NVAX?
The Merck pill has results of a clinical trial, cuts risk of hospitalization in half for high-risk people early in their infections. Clinical trial of 774 persons.
Moderna and BioNTech are equally hit, VXRT too, NVAX the worst.
Busch is my favorite. Especially in quart glass bottles if you can get them anymore. That's Busch, not Busch Lite, which is OK, but Busch is the payoff.
Regarding SP, Fri thru today, today even Sorrento was hit. Federal Reserve and the yield on the 10year Treasury up in a short time from 1.33% to 1.5% making bonds more attractive than equities. So how long will it take for this storm to blow over? Now that share prices are more attractive, buyers spotting a bargain should show up to equalize things. I think.
Regarding SP, Fri thru today, Federal Reserve and the yield on the 10year Treasury up in a short time from 1.33% to 1.5% making bonds more attractive than equities. So how long will it take for this storm to blow over? Now that share prices are more attractive, buyers spotting a bargain should show up to equalize things. I think.
You're welcome. So as a public service announcement to all interested Sorrentians (those who want to expand their knowedge) here is my canned speech:
1. effect, noun, examples: have an effect on someone, or the Casimir effect. Derivatives: effective. In very common use.
2. effect, verb, example: to effect this result (same pronunciation, btw, when pronounced carefully), to effect such and such a result. Fairly arcane, rare usage, mostly in technical contexts, not everyday use.
3. affect, noun, pronunciation: AAAA-fect. AAA is the short a like in cat, bat, rat. Rare, arcane technical term from psychology. Some person had a bland or flat affect, it means behavior, presentation of self in public.
4. affect, verb, pronunciation: ah - FECT, similar to uh-FECT the common pronunciation of effect the noun, word in common use, it means -- to have an effect on -- to influence. He affected me, She affected me. This phenomenon or occurrence affected the result or affected the system or affected my frame of mind / state of mind.
There, that's it. Notice summary:
1. effect, noun, in common usage.
2. effect, verb, arcane, technical term, not in common usage
3. affect noun, arcane, technical term from psychology, not in common use
4. affect, verb, in common usage.
If you remember this matrix (headers: noun, verb; rows: effect, affect), you will get it right every time. And not be confused. If your friends and family get it wrong, be patient and diplomatic with them, and maybe set them straight.
A lot of competitors in that market. . . Sorrento is mentioned.
https://www.einnews.com/amp/pr_news/551446966/pain-management-drugs-market-size-to-reach-at-91-6-billion-growing-at-3-8-cagr-by-2027?fbclid=IwAR1oODkxOXX2fFfDJVCyuzd3SAhhGEnFGo-h8v6-XjVp1DTmHjzGD3p9iKU
Cool article in the last issue of Optics & Photonics News, September 2021: Controlling CRISPR by Meeri Kim, about gene editing. Developed in 2016 (Nobel Prize) by biochemist Jennifer Doudna and microbiologist Emmanuelle Charpentier Prize 2020. Genome-editing powerhouse. I think all the biopharma companies are on this. Point here is current development(s).
https://www.osa-opn.org/home/articles/volume_32/september_2021/features/controlling_crispr/
Cool article in the last issue of Optics & Photonics News, September 2021: Controlling CRISPR by Meeri Kim, about gene editing. Developed in 2016 (Nobel Prize) by biochemist Jennifer Doudna and microbiologist Emmanuelle Charpentier Prize 2020. Genome-editing powerhouse. I think all the biopharma companies are on this. Point here is current development(s).
https://www.osa-opn.org/home/articles/volume_32/september_2021/features/controlling_crispr/
Fixed that.
Damn, the whole market is down.
O come, partnerships, come. _Something_ to counteract the combined massive stupidity, ineptitude, and insouciance of this Board of Directors. Ji doesn't give a damn about us everyday investors. We could all go rot in hell as far as he is concerned, he cares about his bonuses, likewise most of the rest of the BoD. They don't care Crap about us. I care about me and I plan to act on it. The first 2/3 smart move I made about a month ago was splitting up my SRNE shares into MRNA, BNTX, and SRNE 1/3, 1/3, 1/3. It should have been 1/2 and 1/2 the first two. I am quite cross with myself about that. The next few days may allay my pain, probably won't.
Correlation? 11:32CT. NVAX +7.47%, MRNA +3.88%, BNTX + 2.62%, SRNE -2.91% Could this have something to do with vaccines?
This is getting a bit old (SRNE down).
https://pjmedia.com/uncategorized/stacey-lennox/2021/09/06/why-in-the-world-is-the-government-disrupting-the-distribution-of-monoclonal-antibodies-now-n1476240
This seems to be mainly in reference to Regeneron
Refer to: https://pjmedia.com/news-and-politics/stacey-lennox/2021/09/06/how-you-can-tell-the-delta-surge-in-florida-is-waning-n1476503
which I just listened to.
Aka in Polish as "Jewish caviar".
SRNE chopped liver.
INO down -3.4%, SRNE down -4.5%, MRNA up +4.2%, BNTX up + 1.8%, VXRT down -2.0% at eod. FWIW.
INO is down similarly. -4.4% compared to SRNE -5.7%. MRNA is up 2.4%, BNTX is recovered to at +0%. NVAX is similar at -5.0%, vXRT at -3.4%.
This was posted on the internet.
https://floridahealthcovid19.gov/monoclonal-antibody-therapy/
about the Regeneron monoclonal antibody treatment which now is available from the Florida Department of Health.
NVAX is up by 7% today, MRNA by 4.6%, BNTX by 1.75%, and SRNE by 1.5%.
It may not be an entirely bad idea for Sorrento to be jumping on the vaccine bandwagon even if late, given how effective the existing ones are (Moderna more than Pfizer/BioNTech), maybe Sorrento can produce an equal or better one. Yes, it distracts from their manpower and resources, so not sure. Plus, therapeutics hold great promise. Unfortunately, it takes so long to get to the end of clinical trials. And then clinical trials of a vaccine. The bitter fact is the FDA seems to be beholden to BigPharma and is dragging their heals granting us any EUA's. But once a Phase 3 is completed successfully, or more than one, complete approval is almost a required act on their part. Yeah, I know, don't hold your breath.
https://www.sciencenews.org/article/covid-coronavirus-vaccines-hospital-cases-rates-unvaccinated?utm_source=Coronavirus_Update&utm_medium=email&utm_campaign=cvupdate090121
USPTO -- Intent to use -- from Reddit
https://uspto.report/TM/90104375
You mean analysts, right? Where you wrote analyst. Right?